VemurafenibFever following off-label use

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 1998卷 / 1期

关键词：

D O I：

10.1007/s40278-024-54306-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：462 / 462

相关论文

共 50 条

[1] FruquintinibPneumothorax following off-label use
[J]. Reactions Weekly, 2024, 2009 (1) : 272 - 272
[2] EnasidenibHepatitis following off-label use
[J]. Reactions Weekly, 2024, 2011 (1) : 174 - 174
[3] IbrutinibAnaemia following off-label use
[J]. Reactions Weekly, 2024, 2007 (1) : 181 - 181
[4] ErdafitinibRetinopathy following off-label use
[J]. Reactions Weekly, 2024, 2001 (1) : 141 - 141
[5] HydroxychloroquineVarious toxicities following off-label use
[J]. Reactions Weekly, 2024, 2006 (1) : 309 - 309
[6] TocilizumabIntestinal perforation following off-label use
[J]. Reactions Weekly, 2024, 1998 (1) : 451 - 451
[7] BlinatumomabNeurotoxicity syndrome following off-label use
[J]. Reactions Weekly, 2024, 1998 (1) : 121 - 121
[8] PropranololVarious toxicities following an off-label use
[J]. Reactions Weekly, 2024, 2013 (1) : 356 - 356
[9] ImmunosuppressantsLack of efficacy following off-label use
[J]. Reactions Weekly, 2024, 2016 (1) : 242 - 242
[10] LorlatinibHyperlipidaemia and hypercholesterolaemia following off-label use
[J]. Reactions Weekly, 2024, 2017 (1) : 271 - 271

← 1 2 3 4 5 →